שווי פעילות לרווח לפני ריבית, מסים ופחת Nautilus Biotechnology (NAUT)

Nautilus Biotechnology (NAUT) is currently in the initial expansion and validation phase of its digital protein analysis system as it strives to bring its products to market. The technological foundation relies on a unique method of decoding biodata within US laboratories. The market trend shows an EV/EBITDA of 0.00, which is attributed to a lack of profitability and high R&D expenditures during the pre-commercial period.

The multiple compares the total enterprise value, including debt, to operating profit before depreciation and amortization, allowing for an assessment of the real value of assets without the influence of the tax regime. For Nautilus Biotechnology (NAUT), which owns an automated protein analysis complex in Washington, this metric reflects the efficiency of capital expenditures in infrastructure, as clearly captured by the company's EV/EBITDA chart.